Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
about
The blood-spinal cord barrier: morphology and clinical implicationsRole of (drug) transporters in imaging in health and disease.Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat dataInhibiting drug efflux transporters improves efficacy of ALS therapeutics[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodentsInhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in MiceFactors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomographyRadiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance proteinPET and SPECT radiotracers to assess function and expression of ABC transporters in vivoA novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrierPilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review.Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics.Improving the transport of chemotherapeutic drugs across the blood-brain barrier.P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil.Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.Advances in plant-based inhibitors of P-glycoprotein.(11)C- and (18)F-Labeled Radioligands for P-Glycoprotein Imaging by Positron Emission Tomography.Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[11C]verapamil PET.Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration
P2860
Q28240807-814479C1-D189-4625-B92B-FE17C3827419Q30854787-87C70B22-001B-4097-8D34-F060851D4D6FQ34100185-9D2E57D4-9754-4FCC-AD0F-1315698B2026Q34824777-32B643C1-9DC8-41C5-BE98-8C0DEFEF18A7Q35148312-109E9B98-1D75-4284-AFD4-15AD1417F373Q35808725-0FD3B166-E399-47E6-9E42-B21A7EB56DD6Q36049576-79260E11-8375-4745-BAC9-892E74FEEC6FQ36386154-334AD0C4-3500-4ACC-9E97-345C7E9F00EFQ36462753-EBAE10DE-C0CD-44BD-AEB5-444B5131CFB2Q36638627-0CA64E3A-93EF-46C6-BAD4-4BF3CF625DC4Q36935382-DCC5B95B-DF93-4696-8C92-CD949807602DQ36947636-EC65F726-D443-4FC6-A88B-EF7631F50354Q36949407-CF79AA85-9D14-42FF-873D-4BA925EE5F7DQ36949859-532C7912-B7D7-4BA9-9CBF-09B25F5A4087Q36953090-1C5A3DFE-0BB9-4BE1-8EAC-1742105FE9EFQ36955931-760781D4-4696-480E-B7E3-B13A246B4EF3Q37164563-625D4C1F-71B6-4FE7-BF42-528F774B9847Q37177013-4587B1C0-48B6-43BC-A80F-71655A6E1BC4Q37185659-DE827428-BD08-4E58-8A1C-F9B666255058Q37854074-5E4C4DAF-70D6-4B89-BAD8-2E6D2B22FAB1Q37864339-78F35CAE-7564-4E9F-BAFF-E06F9BF285EAQ37960529-2463DD0E-C842-4675-95FF-B3007984DCF3Q38058376-516A6A7D-80C6-47FE-99F7-CD5EA625A8A0Q38166961-FFE48732-304D-445B-ADA1-E645AEBADEC7Q38200490-2ADC8E5F-1C89-4456-B214-81C25DC20413Q38756967-A2436C66-6109-450B-870E-BDE17CD419E3Q38819790-1EB17078-22AF-4B7A-A18B-2C14AE890AD2Q38844653-F7F49D98-3835-4CE7-91AF-7E84497CE119Q38856951-F9713899-0560-4E8C-B815-9EBB03C18B72Q39437473-E6FA2D84-312E-419C-A719-E816AF460B67Q39647414-C85019D0-B2E4-4F5C-B441-7461DBA000E3Q40308640-AC961B4A-2B2B-4CC3-ABB8-4B8ED1297F0CQ41690663-85078C2F-788E-445E-BBAE-E5DF33C8AA79Q41823653-96B7EA53-7AED-4A87-A0F2-E0F85C2F3891Q47289321-EA29976B-789A-4B8E-BE78-39706CAA47D4Q47738183-64256D57-B355-4D56-A666-CD9054FAB857Q48294616-D778F550-8619-4F1C-97AC-B62883C57F16Q57137963-B8375DC1-909D-4D7C-BB48-09952CAD3D24
P2860
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Dose-response assessment of ta ...... sing (R)-[(11)C]verapamil PET.
@en
type
label
Dose-response assessment of ta ...... sing (R)-[(11)C]verapamil PET.
@en
prefLabel
Dose-response assessment of ta ...... sing (R)-[(11)C]verapamil PET.
@en
P2093
P2860
P50
P1476
Dose-response assessment of ta ...... sing (R)-[(11)C]verapamil PET.
@en
P2093
Gloria Stundner
Jens P Bankstahl
Johann Stanek
Markus Müller
Martin Meier
Rebecca Brauner
Rudolf Karch
Thomas Wanek
Wolfgang Löscher
Xiaoqi Ding
P2860
P2888
P304
P356
10.1007/S00259-009-1332-5
P577
2009-12-17T00:00:00Z